Introduction
The term "adhesion molecules" refers to those cell surface structures that allow cells to adhere to each other and the extracellular matrix. Cell adhesion molecules (CAMs) enable cancer-related biological processes like survival, detachment, migration, extravasation, and metastasis, and thus play a crucial role in tumorigenesis, tumor progression, and metastasis (1, 2) . Apart from regulating cellcell and cell-matrix interactions, CAMs also influence cell motility, signalling, and differentiation, apoptosis, and gene transcription (3) . Five families of cell adhesion molecules (CAMs) have been identified, which include cadherins, integrins, immunoglobulin superfamily, selectins, and CD44 (4) . To date, reduced, absent, or disorganized expression of CAMs has been observed in a variety of human tumor, including breast, lung, gastric, bladder, prostate, head and neck, and colorectal cancer (5, 6) . ICAM-1 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily of CAMs (7) . ICAM-1 is normally expressed on the surface of various types of cells: leukocytes, endothelial cells, and fibroblasts (8, 9) . There is mounting evi-dence demonstrating that ICAM-1 is also expressed on the surface of many cancer cell types (10) (11) (12) (13) . It has also been proposed that ICAM-1 may be involved in the process of cancer metastases, facilitating the spread of metastatic cancer cells to secondary sites (9) . Moreover, increased ICAM-1 expression enhances tumor growth, while altered ICAM-1 expression could be caused by genetic variation (14) . The ICAM-1 gene, located in chromosome 19p13, has at least two functional biallelic polymorphisms. These two single nucleotide polymorphisms (SNPs), previously described in ICAM-1 gene at codons 241(glycine to arginine substitution; G to A; rs1799969) in exon 4 and 469 (a lysine to glutamic acid substitution; A to G; rs5498) in exon 6, were also shown to modulate the susceptibility for several types of cancers including prostate (15) , colorectal (16) and breast cancers (17) . Recent genome-wide association study has demonstrated a strong correlation between K469E polymorphism and ICAM-1 levels (18). ICAM-1 G241R polymorphism has been demonstrated to be of importance in binding to the Mac-1 form of leucocyte integrin (19) , and therefore affect the adhesive function of ICAM-1. A growing number of studies have studied the relationship between ICAM-1 gene polymorphisms and tumor susceptibility, but their results remain inconsistent. This lack of consistency might be attributable to the presence of genetic heterogeneity across ethnic populations, small sample size limitations, and publication bias. Therefore, to confirm the role of the ICAM-1 K469E and G241R polymorphisms in tumorigenesis, we conducted a comprehensive meta-analysis on eligible case-control studies published to date. To the best of our knowledge, this is the most comprehensive meta-analysis regarding the ICAM-1 K469E and G241R polymorphisms and their association with cancer risk.
Materials and Methods

Search Strategy
A comprehensive literature search of PubMed, Embase, Web of Science, Science Direct, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure databases (last search updated in November 2013) was conducted to identify case-control studies that investigated the association between ICAM-1 K469E and G241R polymorphisms and cancer risk. The search terms were as follows: "cancer or carcinoma or neoplasm or tumor" in combination with "ICAM-1 or CD54" in combination with "polymorphism or variant or mutation." There was no restriction on period, sample size, population, language, or type of report for minimizing potential publication bias. We evaluated potentially relevant genetic association studies by examining their titles and abstracts, and all published studies matching with the eligible criteria were retrieved.
Inclusion and exclusion criteria
Studies included in the meta-analysis were required to meet the following criteria: 1) Case-control studies which evaluated the association between ICAM-1 K469E and/or G241R polymorphisms and cancer risk; 2) study design: either retrospective or nested case-control design; 3) any diagnoses of patients with cancer had to be confirmed by pathological examinations; and 4) independent variables: the genotype and/or allele counts of ICAM-1 K469E polymorphism or G241R polymorphism. The exclusion criteria of the meta-analysis were: 1) case-control studies not focusing on the correlation between ICAM-1 K469E and G241R polymorphisms and cancer risk; 2) studies with duplicate data; 3) studies based on incomplete data; and 4) meta-analyses, letters, reviews and editorial articles. When an individual author published several articles obtained from the same patient population, only the newest or most complete article was included in the analysis.
Data extraction
The data from the published studies were extracted independently by two reviewers (D Cheng and B Liang). The following information was collected from each study: first author's name, year of publication, country of origin, ethnicity, cancer type, genotyping method, source of controls, number of cases and controls, genotype frequency in cases and controls, and Hardy-Winberg equilibrium (HWE). In case of discrepancies, a consensus on each item was reached among the authors.
Statistical analysis
Crude odds ratios (ORs) together with their corresponding 95% CIs were used to assess the strength of association between ICAM-1 K469E or G241R polymorphisms and the risk of cancer. Allele model (mutation (M) allele versus wild (W) allele), dominant model (WM+MM versus WW), recessive model (MM versus WM+WW), homozygote comparison (MM versus WW), and heterozygote comparison (WM versus WW) were evaluated, respectively. Subgroup analyses were done by ethnicity (Asian, European, and America). Between-study heterogeneity was assessed by calculating Q-statistic (Heterogeneity was considered statistically significant if P < 0.10)(20) and quantified using the I 2 value (I 2 < 25% represents no heterogeneity, I 2 = 25-50% represents moderate heterogeneity, I 2 = 50-75% represents large heterogeneity, and I 2 >75% represents extreme heterogeneity) (21) . If results were not heterogeneous, the pooled ORs were calculated by a fixed-effect model; otherwise, a random-effect model was used. The significance of the combined ORs was determined by the Z-test, in which P<0.05 was considered significant. Moreover, relative influence of each study on the pooled estimate was assessed by excluding a single study each time for sensitivity analysis. Begg's funnel plots (22) and Egger's linear regression test (23) were used to evaluate publication bias. All statistical analyses were performed using STATA version 12.0 (STATA Corporation, College Station, TX).
Results
Characteristics of Eligible Studies
The flow chart that displays the study selection process was shown in Fig. 1 . In accordance with the inclusion criteria, 16 articles containing 18 case-control studies were included in the metaanalysis, including 4,844 cancer cases and 5,618 healthy controls. There were 18 case-control studies concerning ICAM-1 K469E polymorphism (15) (16) (17) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , and 6 case-control studies concerning ICAM-1 G241R (24, (27) (28) (29) (30) 33) . For ICAM-1 K469E polymorphism, seven studies were conducted in European populations, six in Asian populations, four in America populations, and one in Oceania populations. Moreover, there were four studies of European populations (28) (29) (30) 33) , one study of Asian populations (24) , and one study of America populations (27) for ICAM-1 G241R polymorphism. The genotype distributions among the controls of all studies were in agreement with HWE except for two studies for K469E (27, 31) and one study for G241R (33) . The detailed characteristics of the eligible studies included in this meta-analysis were shown in Table 1 . 
Quantitative data synthesis
Results of this meta-analysis were shown in Table 2.
ICAM-1 K469E polymorphism
In the overall analysis, we did not find any significant association between ICAM-1 K469E polymorphism and the risk of cancers in all (Fig.2) . The results suggested that the ICAM-1 K469E polymorphism may be not associated with overall cancer risk. As shown in 
ICAM-1 G241R polymorphism
A total of 921 cases and 955 controls from 6 casecontrol studies on the correlation of ICAM-1 G241R polymorphism and cancer risk were included for data synthesis. In general, the overall analysis revealed ICAM-1 G241R polymorphism seemed to be associated with cancer risk (A allele vs. 
Sensitivity analysis
In order to assess the stability of the results of the meta-analysis, sensitivity analysis was performed by sequentially excluding each study. Statistically similar results were obtained after sequentially excluding each study, suggesting the stability of this meta-analysis.
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Publication bias
In this meta-analysis, we performed Begg's funnel plot and Egger's test to access the publication bias. The shape of the funnel plots did not reveal any evidence of obvious asymmetry under all contrast models for ICAM-1 K469E and G241R (Fig.4) . In addition, the P value of Egger's test was 0.633 for ICAM-1 K469E polymorphism, and 0.704 for ICAM-1 G241R polymorphism under the allele model, respectively, providing statistical evidence of funnel plot's symmetry. Therefore, the results revealed that publication bias was not significant in this meta-analysis. 
Discussion
To the best of our knowledge, our meta-analysis represents the most comprehensive investigation on the association between ICAM-1 K469E and G241R polymorphisms and cancer risk. The results suggested that ICAM-1 K469E polymorphism was not associated with cancer susceptibility. Since demographic characteristics influence genotype frequencies, different races have different gene-environment interaction models. Therefore, we conducted a subgroup analysis according to ethnic differences, and the results indicated that there was a significant association between K469E polymorphism and decreased cancer risk in Euro-pean populations, while there were not significant associations in Asian populations and America population. Moreover, ICAM-1 G241R polymorphism displayed significant association with cancer risk, especially in European populations. Recent studies demonstrated that ICAM-1 possibly contributes to tumorigenesis and metastasis (12, 36, 37) . The potential involvement of ICAM-1 expression in cancer invasion and metastasis was reported in melanomas, pancreatic, lung, and oral cancers (34) . Conversely, some studies indicated that increased ICAM-1 expression was correlated with a more favorable prognosis in gastric, breast, and colorectal cancers under the influence of the host immunosurveillance system (38) (39) (40) On the other hand, limitation of this meta-analysis should also be noted. First, heterogeneity can interfere with the interpretation of the results of a meta-analysis, which was unavoidable when combing many studies. Variation in the environmental and genetic background of study participants may contribute to the heterogeneity. Second, small number of included studies may decrease statistical power and even may produce a fluctuated risk estimate. Therefore, this relationship needs to be further confirmed in larger size, welldesigned prospective studies. Third, the interaction of different susceptibility genes and environment factors leaded to the disease, but our study could not assess gene-gene and gene-environment interactions due to the limited information of included studies. Forth, only studies published were included in the meta-analysis, and non-significant or negative findings may be unpublished. Hence, some inevitable publication biases might exist in the results.
Conclusion
This meta-analysis suggested that ICAM-1 G241R polymorphism might be a genetic risk factor for the development of cancer, especially in European populations. In addition, ICAM-1 K469E polymorphism might not act as a cancer risk factor among all subjects. However, subgroup analysis revealed one genetic model (GG vs. AA) presented the relationship with cancer risk in Asian subgroup, and two genetic models (GG+GA vs. AA and GA vs. AA) in European subgroup, respectively. Further studies with large sample size, standardized unbiased genotyping methods, homogeneous cancer patients, wellmatched controls and multiethnic groups would be warranted.
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